WO2012036512A3 - 중간엽 줄기세포의 연골 세포로의 분화 유도를 위한 화합물의 용도 - Google Patents

중간엽 줄기세포의 연골 세포로의 분화 유도를 위한 화합물의 용도 Download PDF

Info

Publication number
WO2012036512A3
WO2012036512A3 PCT/KR2011/006867 KR2011006867W WO2012036512A3 WO 2012036512 A3 WO2012036512 A3 WO 2012036512A3 KR 2011006867 W KR2011006867 W KR 2011006867W WO 2012036512 A3 WO2012036512 A3 WO 2012036512A3
Authority
WO
WIPO (PCT)
Prior art keywords
cartilage
compound
cells
mesenchymal stem
stem cells
Prior art date
Application number
PCT/KR2011/006867
Other languages
English (en)
French (fr)
Other versions
WO2012036512A2 (ko
Inventor
황기철
장양수
한균희
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to US13/823,653 priority Critical patent/US9068166B2/en
Priority to EP11825472.1A priority patent/EP2617415B1/en
Publication of WO2012036512A2 publication Critical patent/WO2012036512A2/ko
Publication of WO2012036512A3 publication Critical patent/WO2012036512A3/ko
Priority to US14/720,479 priority patent/US20150252003A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 중간엽 줄기세포의 연골 세포로의 분화 유도를 위한 화학식 1의 화합물의 용도 및 화학식 1의 화합물에 의해 중간엽 줄기세포로부터 분화 유도된 연골 세포를 포함하는 연골질환 치료용 의약 조성물을 제공한다. 화학식 1의 화합물로 처리된 중간엽 줄기세포는 연골 세포로 특이적으로 분화 유도되므로 이를 이용하면 관절염, 연골 손상, 연골 결손 등의 연골 질환을 효과적으로 치료할 수 있게 된다.
PCT/KR2011/006867 2010-09-16 2011-09-16 중간엽 줄기세포의 연골 세포로의 분화 유도를 위한 화합물의 용도 WO2012036512A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/823,653 US9068166B2 (en) 2010-09-16 2011-09-16 Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes
EP11825472.1A EP2617415B1 (en) 2010-09-16 2011-09-16 Use of a compound for inducing differentiation of mesenchymal stem cells into cartilage cells
US14/720,479 US20150252003A1 (en) 2010-09-16 2015-05-22 Use of a Compound for Inducing Differentiation of Mesenchymal Stem Cells into Cartilage Cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100091081 2010-09-16
KR10-2010-0091081 2010-09-16

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/823,653 A-371-Of-International US9068166B2 (en) 2010-09-16 2011-09-16 Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes
US14/720,479 Division US20150252003A1 (en) 2010-09-16 2015-05-22 Use of a Compound for Inducing Differentiation of Mesenchymal Stem Cells into Cartilage Cells

Publications (2)

Publication Number Publication Date
WO2012036512A2 WO2012036512A2 (ko) 2012-03-22
WO2012036512A3 true WO2012036512A3 (ko) 2012-05-31

Family

ID=45832131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/006867 WO2012036512A2 (ko) 2010-09-16 2011-09-16 중간엽 줄기세포의 연골 세포로의 분화 유도를 위한 화합물의 용도

Country Status (4)

Country Link
US (2) US9068166B2 (ko)
EP (2) EP2617415B1 (ko)
KR (2) KR101362639B1 (ko)
WO (1) WO2012036512A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103992252B (zh) * 2014-05-23 2016-06-22 华中科技大学 一种多巴胺衍生物及分子印迹聚合物制备方法和应用
CN104892470B (zh) * 2015-06-11 2017-04-12 嘉兴学院 制备n‑烷基对甲苯磺酰胺的方法
KR101653197B1 (ko) * 2016-01-29 2016-09-01 을지대학교 산학협력단 섬유아세포의 연골세포로의 교차분화 유도방법
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273844A (en) * 1976-01-26 1981-06-16 Canon Kabushiki Kaisha Heat-developable photosensitive member for forming electrostatic printing masters
US6440966B1 (en) * 1999-01-13 2002-08-27 Warner-Lambert Company Benzenesulfonamide derivatives and their use as MEK inhibitors
KR20030094384A (ko) * 2001-05-07 2003-12-11 스미스클라인 비참 코포레이션 술폰아미드

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216150A (en) 1988-12-26 1993-06-01 Hiroyoshi Hidaka Derivatives of isoquinoline (and naphthalene) sulfonamides
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US6639051B2 (en) * 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
WO2003007931A1 (fr) 2001-06-08 2003-01-30 Institute Of Medicinal Molecular Design. Inc. Derives de sulfonamide
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
GB0317315D0 (en) 2003-07-24 2003-08-27 Astex Technology Ltd Pharmaceutical compounds
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
US7892830B2 (en) * 2007-01-17 2011-02-22 Wisconsin Alumni Research Foundation Clonal culture of human pluripotent stem cells
KR101012869B1 (ko) * 2008-02-05 2011-02-08 동국대학교 산학협력단 지방기원 중간엽 줄기세포를 연골세포로 분화시키는 방법
WO2009116840A2 (en) * 2008-03-21 2009-09-24 Industry-Academic Cooperation Foundation, Yonsei University Chemical reagents regulating stem cell fate
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273844A (en) * 1976-01-26 1981-06-16 Canon Kabushiki Kaisha Heat-developable photosensitive member for forming electrostatic printing masters
US6440966B1 (en) * 1999-01-13 2002-08-27 Warner-Lambert Company Benzenesulfonamide derivatives and their use as MEK inhibitors
KR20030094384A (ko) * 2001-05-07 2003-12-11 스미스클라인 비참 코포레이션 술폰아미드

Also Published As

Publication number Publication date
EP2617415A2 (en) 2013-07-24
WO2012036512A2 (ko) 2012-03-22
KR20120029367A (ko) 2012-03-26
EP2617415B1 (en) 2016-04-20
KR20130103481A (ko) 2013-09-23
US20150252003A1 (en) 2015-09-10
EP2617415A4 (en) 2014-03-05
US20130236969A1 (en) 2013-09-12
EP3056198A2 (en) 2016-08-17
KR101524929B1 (ko) 2015-06-01
US9068166B2 (en) 2015-06-30
KR101362639B1 (ko) 2014-02-13

Similar Documents

Publication Publication Date Title
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
GEP20135964B (en) Inhibitors of beta-secretase
WO2011008773A3 (en) Mesenchymal stem cell differentiation
MX2012004114A (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
WO2013122888A3 (en) Methods of treating bacterial infections
PL2620156T3 (pl) Kompozycja farmaceutyczna do zapobiegania lub leczenia chorób immunologicznych lub chorób zapalnych, zawierająca komórki macierzyste traktowane agonistą NOD2 lub jego produktem hodowlanym
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
HRP20141057T1 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
MX2012004780A (es) Inhibidores de akt.
ZA201204634B (en) Process for the treatment of plant biomass
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
PL2429507T3 (pl) Kompozycja farmaceutyczna wolna od fosforanów do leczenia jaskry
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
IL209360A (en) Medications containing pm00104 for the treatment of multiple myeloma
WO2012017321A3 (en) Treatment for dyslipidemia
WO2012036512A3 (ko) 중간엽 줄기세포의 연골 세포로의 분화 유도를 위한 화합물의 용도
WO2011029639A3 (en) Compounds and methods for treating neoplasia
WO2012031118A3 (en) Cell permeable inhibitors of anaphase promoting complex
BRPI0908376A2 (pt) Ciclosporina não imunossupressiva para o tratamento de uma distrofia muscular
WO2012024670A3 (en) Composition and methods for treating glioblastoma
EP2611446A4 (en) CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR THE PREPARATION OF THE AMORPHOUS FORM OF MARAVIROC
EP2387565A4 (en) 2,4-PYRIMIDINDIAMIN COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2012051251A8 (en) Methods of treating giardiasis
EP2529728A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11825472

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13823653

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011825472

Country of ref document: EP